HQ Team
August 1, 2024: French drugmaker Sanofi SA will build a 1.3 billion euro ($1.4 billion) insulin manufacturing facility in Germany’s Frankfurt to secure the long-term supply of the medicine.
The factory, to be built at the company’s BioCampus situated in Frankfurt Höchst, about 20 kilometers west of Frankfurt City Center, will also “strengthen European security of supply,” according to a company statement.
The investment will be spread over the next five years. The insulin plant covers an area of around 36,000 square meters, which is roughly the size of five football fields.
“With this project, we are reaffirming our commitment to diabetes patients worldwide and leveraging the many years of expertise at our Frankfurt BioCampus with its highly qualified employees,” said Brendan O’Callaghan, Chairman of the Supervisory Board of Sanofi in Germany and Sanofi Global Head of Manufacturing & Supply.
‘European health sovereignty’
“Sanofi has a long history of developing strategic platforms to secure the supply of important medicines and vaccines for the present and future. And our commitment to promoting European health sovereignty remains distinctive and unique.
“As one of the world’s largest manufacturers of insulin, we remain committed to producing this essential medicine for the growing number of people with diabetes around the world,” he said.
The new plant will replace existing insulin production plants. The new facility covers the entire insulin production chain, from active ingredient production to the manufacture of cartridges and ampoules, the assembly of pens and auto-injectors and global distribution. Sanofi’s insulin is branded as Lantus.
Rise in global demand
In 2022, the global diabetes drugs market was valued at $66.15 billion and is expected to grow to $134.08 billion by 2030. This would be a compound annual growth rate (CAGR) of 7.8% over the period.
In 2022, the global diabetes management market was valued at $18.23 billion and is expected to grow to $36.02 billion by 2030 at the rate of a compound annual growth rate of CAGR 8.87% over the period.
In the period to 2031, the global Type 2 diabetes market is expected to grow at a CAGR of 8.20%. In 2022 it was valued at $32 billion and is expected to grow to $59.45 billion by 2031. The monitoring device sector is expected to be a major part of this market, according to Skyquest.
